Literature DB >> 23307327

A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries.

Daniel Satgé1, Charles A Stiller, Stefan Rutkowski, André O von Bueren, Brigitte Lacour, Danièle Sommelet, Motoi Nishi, Maura Massimino, Maria Luisa Garré, Florencia Moreno, Henrik Hasle, Zsuzsanna Jakab, Mark Greenberg, Nicolas von der Weid, Claudia Kuehni, Oscar Zurriaga, Maria-Luisa Vicente, Rafael Peris-Bonet, Martin Benesch, Michel Vekemans, Sheena G Sullivan, Christian Rickert.   

Abstract

Persons with Down syndrome (DS) uniquely have an increased frequency of leukemias but a decreased total frequency of solid tumors. The distribution and frequency of specific types of brain tumors have never been studied in DS. We evaluated the frequency of primary neural cell embryonal tumors and gliomas in a large international data set. The observed number of children with DS having a medulloblastoma, central nervous system primitive neuroectodermal tumor (CNS-PNET) or glial tumor was compared to the expected number. Data were collected from cancer registries or brain tumor registries in 13 countries of Europe, America, Asia and Oceania. The number of DS children with each category of tumor was treated as a Poisson variable with mean equal to 0.000884 times the total number of registrations in that category. Among 8,043 neural cell embryonal tumors (6,882 medulloblastomas and 1,161 CNS-PNETs), only one patient with medulloblastoma had DS, while 7.11 children in total and 6.08 with medulloblastoma were expected to have DS. (p 0.016 and 0.0066 respectively). Among 13,797 children with glioma, 10 had DS, whereas 12.2 were expected. Children with DS appear to be specifically protected against primary neural cell embryonal tumors of the CNS, whereas gliomas occur at the same frequency as in the general population. A similar protection against neuroblastoma, the principal extracranial neural cell embryonal tumor, has been observed in children with DS. Additional genetic material on the supernumerary chromosome 21 may protect against embryonal neural cell tumor development.

Entities:  

Mesh:

Year:  2013        PMID: 23307327     DOI: 10.1007/s11060-012-1041-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Impact of prenatal diagnosis on the prevalence of live births with Down syndrome in the eastern half of Switzerland 1980-1996.

Authors:  Franz Binkert; Michael Mutter; Albert Schinzel
Journal:  Swiss Med Wkly       Date:  2002-08-24       Impact factor: 2.193

2.  A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000.

Authors:  Babak Khoshnood; Catherine De Vigan; Véronique Vodovar; Janine Goujard; François Goffinet
Journal:  BJOG       Date:  2004-05       Impact factor: 6.531

Review 3.  No paradox, no progress: inverse cancer comorbidity in people with other complex diseases.

Authors:  Rafael Tabarés-Seisdedos; Nancy Dumont; Anaïs Baudot; Jose M Valderas; Joan Climent; Alfonso Valencia; Benedicto Crespo-Facorro; Eduard Vieta; Manuel Gómez-Beneyto; Salvador Martínez; John L Rubenstein
Journal:  Lancet Oncol       Date:  2011-04-15       Impact factor: 41.316

4.  Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas.

Authors:  Stefan Pfister; Marc Remke; Grischa Toedt; Wiebke Werft; Axel Benner; Frank Mendrzyk; Andrea Wittmann; Frauke Devens; Katja von Hoff; Stefan Rutkowski; Andreas Kulozik; Bernhard Radlwimmer; Wolfram Scheurlen; Peter Lichter; Andrey Korshunov
Journal:  Genes Chromosomes Cancer       Date:  2007-09       Impact factor: 5.006

5.  Population-based epidemiologic data on brain tumors in German children.

Authors:  P Kaatsch; C H Rickert; J Kühl; J Schüz; J Michaelis
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

Review 6.  Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma.

Authors:  D Satgé; P Monteil; A J Sasco; A Vital; H Ohgaki; A Geneix; P Malet; M Vekemans; M O Réthoré
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

7.  Childhood central nervous system tumours--incidence and survival in Europe (1978-1997): report from Automated Childhood Cancer Information System project.

Authors:  Rafael Peris-Bonet; Carmen Martínez-García; Brigitte Lacour; Svetlana Petrovich; Begoña Giner-Ripoll; Aurora Navajas; Eva Steliarova-Foucher
Journal:  Eur J Cancer       Date:  2006-09       Impact factor: 9.162

8.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

9.  The profile and incidence of cancer in Down syndrome.

Authors:  S G Sullivan; R Hussain; E J Glasson; A H Bittles
Journal:  J Intellect Disabil Res       Date:  2007-03

10.  Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study.

Authors:  Charlotte K Ekelund; Finn Stener Jørgensen; Olav Bjørn Petersen; Karin Sundberg; Ann Tabor
Journal:  BMJ       Date:  2008-11-27
View more
  5 in total

1.  Chronic up-regulation of the SHH pathway normalizes some developmental effects of trisomy in Ts65Dn mice.

Authors:  Tara Dutka; Dorothy Hallberg; Roger H Reeves
Journal:  Mech Dev       Date:  2014-12-12       Impact factor: 1.882

Review 2.  SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.

Authors:  Ross Mangum; Elizabeth Varga; Daniel R Boué; David Capper; Martin Benesch; Jeffrey Leonard; Diana S Osorio; Christopher R Pierson; Nicholas Zumberge; Felix Sahm; Daniel Schrimpf; Stefan M Pfister; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2016-07-21       Impact factor: 1.475

Review 3.  The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System.

Authors:  Daniel Satgé; Markus G Seidel
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

4.  Medulloblastoma Associated with Down Syndrome: From a Rare Event Leading to a Pathogenic Hypothesis.

Authors:  Alessandra Boni; Marco Ranalli; Giada Del Baldo; Roberto Carta; Mariachiara Lodi; Emanuele Agolini; Martina Rinelli; Diletta Valentini; Sabrina Rossi; Viola Alesi; Antonella Cacchione; Evelina Miele; Iside Alessi; Anna Maria Caroleo; Giovanna Stefania Colafati; Maria Antonietta De Ioris; Luigi Boccuto; Mario Balducci; Andrea Carai; Angela Mastronuzzi
Journal:  Diagnostics (Basel)       Date:  2021-02-07

5.  Low risk of solid tumors in persons with Down syndrome.

Authors:  Henrik Hasle; Jan M Friedman; Jørgen H Olsen; Sonja A Rasmussen
Journal:  Genet Med       Date:  2016-03-31       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.